Bibliography

Matrix Metalloproteinases >>

Urinary FGFR3 >>

Tissue FGFR3 >>

DNA Methylation Markers >>

• 1. Fernandez CA, Wszolek MF, Loughlin, KR, Libertino JA, Summerhayes IC, Shuber AP. A Novel approach to using matrix metalloproteinases for bladder cancer. J Urol 2009 Nov; 182(5) 2188-94.
• 2. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased Incidence of Matrix Metalloproteinases in Urine of Cancer Patients. Cancer Res. 1998 Apr 1;58(7):1395-9. 
• 3. Kanayama H. Matrix metalloproteinases and bladder cancer. J Med Invest. 2001 Feb;48(1-2):31-43.
• 4. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, Schnorr D, Loening SA. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology. 2001 Apr;57(4):675-9. 
• 5. Eissa S, Ali-Labib R, Swellam M, Bassiony M, Tash F, El-Zayat TM. Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine. Eur Urol. 2007 Nov;52(5):1388-96. 
• 6. Roy R, Louis G, Loughlin KR, Wiederschain D, Kilroy SM, Lamb CC, Zurakowski D, Moses MA. Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res. 2008 Oct 15;14(20):6610-17. 
• 7. Ozdemir E, Kakehi Y, Okuno H, Yoshida O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol. 1999 Apr;161(4):1359-63. 
• 8. Vasala K, Pääkko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein in urinary bladder cancer: a marker of favorable prognosis. Anticancer Res. 2008 May-Jun;28(3B):1757-61. 
• 9. Kader AK, Liu J, Shao L, Dinney CP, Lin J, Wang Y, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res. 2007 May 1;13(9):2614-20. 
• 10. Kader AK, Shao L, Dinney CP, Schabath MB, Wang Y, Liu J, Gu J, Grossman HB, Wu X. Matrix metalloproteinase polymorphisms and bladder cancer risk. Cancer Res. 2006 Dec 15;66(24):11644-8.
• 11. Choi YD, Cho NH, Ahn HS, Cho KS, Cho SY, Yang WJ. Matrix metalloproteinase expression in the recurrence of superficial low grade bladder transitional cell carcinoma. J Urol. 2007 Mar;177(3):1174-8. 
• 12. Staack A, Badendieck S, Schnorr D, Loening SA, Jung K. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder. BMC Urol. 2006 Aug 10;6:19. 
• 13. Di Carlo A, Terracciano D, Mariano A, Macchia V. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep. 2006 May;15(5):1321-6. 
• 14. Wallard MJ, Pennington CJ, Veerakumarasivam A, Burtt G, Mills IG, Warren A, Leung HY, Murphy G, Edwards DR, Neal DE, Kelly JD. Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma. Br J Cancer. 2006 Feb 27;94(4):569-77. 
• 15. Eissa S, Labib RA, Mourad MS, Kamel K, El-Ahmady O. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer. Eur Urol. 2003 Dec;44(6):687-94. 
• 16. Vasala K, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology. 2003 Nov;62(5):952-7. 
• 17. Fröhlich C, Albrechtsen R, Dyrskjøt L, Rudkjaer L, Ørntoft TF, Wewer UM. Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res. 2006 Dec 15;12(24):7359-68. 

• 18. Zuiverloon T; van der Aa M; van der Kwast T; Steyerberg E; Lingsma H; Bangma C; Zwarthoff E. Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle–Invasive Bladder Cancer. Clin Cancer Res. 2010 June;16(11):3011-3018. 
• 19. Kompier LC, van der Aa MN, Lurkin I, Vermeij M, Kirkels WJ, Bangma CH, van der Kwast TH, Zwarthoff EC. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol. 2009 May;218(1):104-12. 
• 20. van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW. FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours. Eur Urol. 2008 Jun; 55(3):650-658. 
• 21. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007 Dec;25(6):581-93. 
• 22. Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia. 2008 Jan;10(1):1-7. 
• 23. Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, Zwarthoff EC. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol. 2008 Oct;54(4):835-43. 
• 24. Burger M, Catto J, van Oers J, Zwarthoff E, Hamdy FC, Meuth M, Azzouri AR, Cussenot O, Wild PJ, Stoehr R, Hartmann A. Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract.  Verh Dtsch Ges Pathol. 2006;90:244-52. 
• 25. Junker K, van Oers JM, Zwarthoff EC, Kania I, Schubert J, Hartmann A. Correlation of FGFR3 mutations and chromosomal alterations in bladder cancer. Verh Dtsch Ges Pathol. 2006;90:151-8. 
• 26. van Oers JM, Wild PJ, Burger M, Denzinger S, Stoehr R, Rosskopf E, Hofstaedter F, Steyerberg EW, Klinkhammer-Schalke M, Zwarthoff EC, van der Kwast TH, Hartmann A. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol. 2007 Sep;52(3):760-8. 
• 27. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res. 2005 Nov 1;11(21):7743-8. 
• 28. van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER, Jöbsis AC, Zwarthoff EC. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004 Mar 15;64(6):1911-4. 
• 29. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003 May 15;21(10):1912-21. 
• 30. van Rhijn BW, Lurkin I, Chopin DK, Kirkels WJ, Thiery JP, van der Kwast TH, Radvanyi F, Zwarthoff EC. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. Clin Cancer Res. 2003 Jan;9(1):257-63. 
• 31. van Rhijn BW, Montironi R, Zwarthoff EC, Jöbsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 2002 Oct;198(2):245-51. 
• 32. Rieger-Christ KM, Mourtzinos A, Lee PJ, Zagha RM, Cain J, Silverman M, Libertino JA, Summerhayes IC.  Identification of Fibroblast Growth Factor Receptor 3 Mutations in Urine Sediment DNA Samples Complements Cytology in Bladder Tumor Detection. CANCER 2003 Aug;98(4) 737-744. 

• 33. Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, Wieland WF, Hofstaedter F, Hartmann A, Zwarthoff EC. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study. Eur Urol. 2008 Oct;54(4):835-43. 
• 34. Cheng L; Zhang S; Davidson D; MacLennan G; O Koch M; Montironi R; Lopez-Beltran. Molecular Determinates of Tumor Recurrence in the Urinary Bladder. Future Oncol. 2009;5(6):843-857. 
• 35. Hernandez S; Lopez-Knowles E; Lloreta J; Kogevinas M; Amoros A; Tardon A; Carrato A; Serra C; Malats N; Real F. Prospective Study of FGFR3 Mutations As a Prognostic Factor in Nonmuscle Invasive Urothelial Bladder Carcinomas. J Clin Oncol. 2006 Aug;24:3664-3671. 
• 36. Kompier LC, van der Aa MN, Lurkin I, Vermeij M, Kirkels WJ, Bangma CH, van der Kwast TH, Zwarthoff EC. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol. 2009 May;218(1):104-12. 
• 37. Kompier L; van Tilborg A; Zwarthoff E. Bladder cancer: Novel molecular characteristics, diagnostic, and therapeutic implications. Urol Oncol. 2010;28:91-96. 
• 38. van Oers J; Wild P, Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter; Steyerberg E; Klinkhammer-Schalke M; Zwarthoff E; van der Kwast T; Hartmann A. FGFR3 Mutations and a Normal CK20 Staining Pattern Define Low-Grade Noninvasive Urothelial Bladder Tumours. Eur Urol. 2007 Jan;52:760-768. 
• 39. van Rhijn B; Vis N; van der Kwast T; Kirkels W; Radvanyi F; Ooms E; Chopin D; Boeve´ E; Jobsis A; Zwarthoff E. Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical Outcome. J Clin Oncol. 2003 May;21(10):1912-1921. 

• 40. Renard, I., Joniau, S., van Cleyenbreugel, B., Collette, C., Naome, C., Vlassenbroeck, I., Nicolas, H., de Leval, J., Straub, J., Van Criekinge, W., Hamida, W., Hellel, M., Thomas, A., de Leval, L., Bierau, K., Waltregny, D.: Identification and Validation of the Methylation Specific Polymerase Chain Reaction Assays for the NonInvasive Detection of Primary Bladder Cancer in Urine Samples. Eur Urol (2009), doi: 10.1016/j.eururo.2009.07.041.
•  41. Costa, V., Henrique, R., Danielsen, S., Duarte-Pereira, S., Eknaes, M., Skotheim, R., Rodrigues, A., Magalhaes, J., Oliveira, J., Lothe, R., Teixeira, M., Jeronimo, C., and Lind, G.  Three Epigenetic Biomarkers, GDF15, TMEFF2, and VIM, Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples.  Clin Cancer Res; 2010 Dec; 16(23): 5842-5851.